

Medication use in public pharmacies

KEY DATA SUMMARY

Analysis of the distribution and evolution of medication consumption in Belgium, in terms of volume and expenditure per insured (analysis and trends by region, province and district), for the year **2023**



NIHDI – Healthcare Service – Directorate for Research, Development and Quality promotion

Appropriate care unit

Pascal Meeus, Lies Grypdonck, Virginie Dalcq, Benjamin Swine, Marc De Falleur, Katrien Declercq, Delphine Beauport

Contact: appropriatecare@riziv-inami.fgov.be

Date of report: 2 December 2024

CONTENTS

CONTENTS.....	2
1. INTRODUCTION	4
2. ALIMENTARY TRACT & METABOLISM	5
Insulins and analogues.....	5
Proton pump inhibitors.....	6
Blood glucose lowering drugs except insulins	7
3. BLOOD & BLOOD FORMING ORGANS	8
Antiaggregants	8
Oral anticoagulants	9
Heparin group	10
4. CARDIOVASCULAR SYSTEM	11
Cardiovascular system drugs	11
Antiarrhythmics (class I & III)	12
Lipid-modifying agents.....	13
5. SYSTEMIC HORMONAL PREPARATIONS	14
Levothyroxine (Thyroid hormone)	14
6. ANTIINFECTIVES FOR SYSTEMIC USE	15
Antibiotics - All prescribers	15
Antibiotics (Amoxicillin) - All prescribers	16
Antibiotics - General medicine.....	17
Antibiotics - Paediatrics	18
Antibiotics - Gynaecology	19
Antibiotics - Internal medicine.....	20
Antibiotics - Gastroenterology	21
Antibiotics - Pneumology	22
Antibiotics - Surgery	23
Antibiotics - Urology	24
Antibiotics - Plastic surgery.....	25
Antibiotics - Dentistry	26
Antibiotics - Periodontology	27

Medication use – SUMMARY

7. MUSCULO-SKELETAL SYSTEM	28
Antigout preparations.....	28
Drugs affecting bone structure and mineralization.....	29
Non-steroidal anti-inflammatory drugs (NSAID).....	30
8. NERVOUS SYSTEM.....	31
Antidepressants	31
Antipsychotics	32
Antivertigo preparations.....	33
Dopaminergic agents (anti-parkinson drug)	34
Gabapentinoids.....	35
Methylphenidate	36
Opioids	37
Antimigraine preparation	38
9. RESPIRATORY SYSTEM	39
Antihistamines for systemic use	39
Drugs for obstructive airway diseases	40
10. SENSORY ORGANS.....	41
Antiglaucoma preparations and miotics	41
11. IMMUNITY	42
Vaccination against influenza (65+/excl. nursing homes)	42
12. CROSS-SYSTEM ANALYSES	43
Polypharmacy (65 years and older)	43
Anticholinergics (65 years and older)	44
13. FOOTNOTES.....	45

1. INTRODUCTION

The Appropriate Care Unit was set up within the NIHDI's Directorate for Research, Development and Quality under NIHDI's Administration Contract for 2016-2018¹. Article 35 of this contract refers to 'the setting up of an Appropriate Care Unit, aiming specifically to promote an integrated approach to the rational use of resources'. The Appropriate Care Unit has been up and running since the second quarter of 2017.

The tasks of the Unit were set out formally in the '2016-2017 Healthcare monitoring Action plan', published by NIHDI on 18 July 2016. This plan lists around thirty measures designed to make healthcare provision more efficient, by encouraging appropriate practice and tackling unnecessary or inappropriate care.

The plan states that one of the tasks of the Appropriate Care Unit is to analyse the 'appropriateness of care', in order to identify unexplained variations in consumption patterns, identified after standardisation. Such variations can potentially point to non-optimal use of resources.

"Medication use" documents report on the analyses carried out in this framework. Each report focuses on a particular topic.

In this document, we present the key data from each report relating to analyses of insured consumers of Cardiovascular drugs – Lipid-modifying agents and of the volumes dispensed within the framework of the health insurance (assimilated to their consumption). Readers interested in the methodology used in these quantitative analyses should consult the document entitled '[Variations in consumption – Methodology](#)'.

We have deliberately chosen not to attempt to interpret the figures, preferring to present the results to experts who are in a better position to do so. This document has nevertheless been made available to the public in order to provide objective, open input to discussions on this issue.

¹ (National Institute for Health and Disability Insurance, 2016)

2. ALIMENTARY TRACT & METABOLISM

Insulins and analogues

Main prescribers:	<i>Endocrinology-diabetology</i>	43%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		1,2%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		1,48%
Median age		67 y.
Max/min ratio ² of the median age (by district*)		1,11
Percentage of women		45,8%
Ratio Preferential rate/General rate		2,22
Coefficient of variation (2023)		11,9%
Max/min ratio ² of percentage of insured consumers (by district*)		1,5
CONSUMPTION		
Annual consumption (DDD)		78.437.523
Consumption of DDD (per 100.000 insured persons)		680.851
Average annual consumption per insured consumer (in DDD)		461
Percentage insured consumers with more than 3 times the average consumption		2,82%
Coefficient of variation ³ (2013-2015)	13,69%	NS
Coefficient of variation ³ (2021-2023)	15,71%	
Trend ⁴ (2013-2023)	0,37%	*
Trend ⁵ (2013-2021)	0,66%	***
Trend ⁵ (2021-2023)	-0,81%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		86.440.617€
Average annual expenditure per insured		7,5€
Average patient share per insured consumer		0,0%
Max/Min Ratio ² of expenditure per insured (by district*)	1,75	
Percentage low-cost medication	31,3%	
Trend (2013-2023)	-0,38%	
Trend (2021-2023)	-3,95%	

Link to the report: [RAPPORT-EN-Antidiabetiques_Insulines et analogues 2023.pdf](#)

Medication use – SUMMARY

Proton pump inhibitors

Main prescribers:	General practitioners	80%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	0,0%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	20,62%	
Median age	61 y.	
Max/min ratio ² of the median age (by district*)	1,05	
Percentage of women	58,0%	
Ratio Preferential rate/General rate	1,35	
Coefficient of variation (2023)	7,6%	
Max/min ratio ² of percentage of insured consumers (by district*)	1,33	
CONSUMPTION		
Annual consumption (DDD)	449.509.004	
Consumption of DDD (per 100.000 insured persons)	3.901.817	
Average annual consumption per insured consumer (in DDD)	189	
Percentage insured consumers with more than 3 times the average consumption	3,77%	
Coefficient of variation ³ (2013-2015)	14,07%	NS
Coefficient of variation ³ (2021-2023)	12,26%	
Trend ⁴ (2013-2023)	2,09%	***
Trend ⁵ (2013-2021)	2,41%	NS
Trend ⁵ (2021-2023)	0,80%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	109.460.799€	
Average annual expenditure per insured	9,5€	
Average patient share per insured consumer	22,5%	
Max/Min Ratio ² of expenditure per insured (by district*)	1,7	
Percentage low-cost medication	100,0%	
Trend (2013-2023)	0,77%	
Trend (2021-2023)	1,63%	

Link to the report: [RAPPORT-EN-Inhibiteurs de la pompe a protons 2023.pdf](#)

Medication use – SUMMARY

Blood glucose lowering drugs except insulins

Main prescribers:	<i>General practitioners</i>	76%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		5,4%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		6,74%
Median age		68 y.
Max/min ratio ² of the median age (by district*)		1,13
Percentage of women		47,3%
Ratio Preferential rate/General rate		1,68
Coefficient of variation (2023)		19,0%
Max/min ratio ² of percentage of insured consumers (by district*)		1,8
CONSUMPTION		
Annual consumption (DDD)		287.491.382
Consumption of DDD (per 100.000 insured persons)		2.495.476
Average annual consumption per insured consumer (in DDD)		370
Percentage insured consumers with more than 3 times the average consumption		5,46%
Coefficient of variation ³ (2013-2015)		16,06%
Coefficient of variation ³ (2021-2023)		14,21%
Trend ⁴ (2013-2023)		2,70%
Trend ⁵ (2013-2021)		1,96%
Trend ⁵ (2021-2023)		5,69%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		230.304.508€
Average annual expenditure per insured		19,99€
Average patient share per insured consumer		0,8%
Max/Min Ratio ² of expenditure per insured (by district*)		1,76
Percentage low-cost medication		70,4%
Trend (2013-2023)		10,43%
Trend (2021-2023)		17,43%

Link to the report:

[RAPPORT-EN-Antidiabetiques_Hypoglycemiants_a_l'exception_des_insulines_2023.pdf](#)

3. BLOOD & BLOOD FORMING ORGANS

Antiaggregants

Main prescribers:	General practitioners	78%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		2,7%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	8,57%	
Median age	72 y.	
Max/min ratio ² of the median age (by district*)	1,04	
Percentage of women	46,1%	
Ratio Preferential rate/General rate	1,35	
Coefficient of variation (2023)	10,8%	
Max/min ratio ² of percentage of insured consumers (by district*)	1,53	
CONSUMPTION		
Annual consumption (DDD)	353.274.580	
Consumption of DDD (per 100.000 insured persons)	3.066.485	
Average annual consumption per insured consumer (in DDD)	358	
Percentage insured consumers with more than 3 times the average consumption	0,39%	
Coefficient of variation ³ (2013-2015)	11,77%	NS
Coefficient of variation ³ (2021-2023)	12,77%	
Trend ⁴ (2013-2023)	-0,88%	***
Trend ⁵ (2013-2021)	-0,15%	***
Trend ⁵ (2021-2023)	-3,78%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	27.084.811€	
Average annual expenditure per insured	2,35€	
Average patient share per insured consumer	14,2%	
Max/Min Ratio ² of expenditure per insured (by district*)	1,64	
Percentage low-cost medication	11,2%	
Trend (2013-2023)	-3,02%	
Trend (2021-2023)	-1,81%	

Link to the report: [RAPPORT-EN-Antiagregants_2023.pdf](#)

Medication use – SUMMARY

Oral anticoagulants

Main prescribers:	General practitioners	77%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	0,1%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	3,51%	
Median age	78 y.	
Max/min ratio ² of the median age (by district*)	1,05	
Percentage of women	46,5%	
Ratio Preferential rate/General rate	1,27	
Coefficient of variation (2023)	6,6%	
Max/min ratio ² of percentage of insured consumers (by district*)	1,25	
CONSUMPTION		
Annual consumption (DDD)	99.857.963	
Consumption of DDD (per 100.000 insured persons)	866.785	
Average annual consumption per insured consumer (in DDD)	247	
Percentage insured consumers with more than 3 times the average consumption	0,09%	
Coefficient of variation ³ (2013-2015)	18,19%	NS
Coefficient of variation ³ (2021-2023)	9,15%	
Trend ⁴ (2013-2023)	8,14%	***
Trend ⁵ (2013-2021)	9,28%	***
Trend ⁵ (2021-2023)	3,69%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	259.823.444€	
Average annual expenditure per insured	22,55€	
Average patient share per insured consumer	6,1%	
Max/Min Ratio ² of expenditure per insured (by district*)	1,44	
Percentage low-cost medication	NA	
Trend (2013-2023)	16,12%	
Trend (2021-2023)	5,54%	

Link to the report: [RAPPORT-EN-Anticoagulants_oraux_2023.pdf](#)

Medication use – SUMMARY

Heparin group

Main prescribers:	<i>General practitioners</i>	41%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		2,7%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		2,89%
Median age		60 y.
Max/min ratio ² of the median age (by district*)		1,05
Percentage of women		59,9%
Ratio Preferential rate/General rate		1,22
Coefficient of variation (2023)		18,9%
Max/min ratio ² of percentage of insured consumers (by district*)		1,87
CONSUMPTION		
Annual consumption (DDD)		20.351.302
Consumption of DDD (per 100.000 insured persons)		176.653
Average annual consumption per insured consumer (in DDD)		61
Percentage insured consumers with more than 3 times the average consumption		4,81%
Coefficient of variation ³ (2013-2015)		24,24%
Coefficient of variation ³ (2021-2023)		30,74%
Trend ⁴ (2013-2023)		-5,22%
Trend ⁵ (2013-2021)		-4,43%
Trend ⁵ (2021-2023)		-8,29%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		30.888.717€
Average annual expenditure per insured		2,68€
Average patient share per insured consumer		20,6%
Max/Min Ratio ² of expenditure per insured (by district*)		2,5
Percentage low-cost medication		4,3%
Trend (2013-2023)		-5,55%
Trend (2021-2023)		-7,08%

Link to the report: [RAPPORT-EN-Groupe_des_heparines_2023.pdf](#)

4. CARDIOVASCULAR SYSTEM

Cardiovascular system drugs

Main prescribers:	General practitioners	82%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		3,4%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		28,69%
Median age		67 y.
Max/min ratio ² of the median age (by district*)		1,08
Percentage of women		52,4%
Ratio Preferential rate/General rate		1,15
Coefficient of variation (2023)		5,7%
Max/min ratio ² of percentage of insured consumers (by district*)		1,21
CONSUMPTION		
Annual consumption (DDD)		2.108.666.863
Consumption of DDD (per 100.000 insured persons)		18.303.597
Average annual consumption per insured consumer (in DDD)		638
Percentage insured consumers with more than 3 times the average consumption		3,77%
Coefficient of variation ³ (2013-2015)		8,79%
Coefficient of variation ³ (2021-2023)		7,53% NS
Trend ⁴ (2013-2023)	-0,58%	***
Trend ⁵ (2013-2021)	-0,88%	***
Trend ⁵ (2021-2023)	0,65%	***
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		463.767.154€
Average annual expenditure per insured		40,26€
Average patient share per insured consumer		19,0%
Max/Min Ratio ² of expenditure per insured (by district*)		1,54
Percentage low-cost medication		87,4%
Trend (2013-2023)	-2,79%	
Trend (2021-2023)	9,42%	

Link to the report: [RAPPORT-EN-Medication du système cardio-vasculaire 2023.pdf](#)

Medication use – SUMMARY

Antiarrhythmics (class I & III)

Main prescribers:	<i>General practitioners</i>	76%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		1,9%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		1,24%
Median age		76 y.
Max/min ratio ² of the median age (by district*)		1,04
Percentage of women		49,7%
Ratio Preferential rate/General rate		1,11
Coefficient of variation (2023)		27,9%
Max/min ratio ² of percentage of insured consumers (by district*)		2,55
CONSUMPTION		
Annual consumption (DDD)		32.239.971
Consumption of DDD (per 100.000 insured persons)		279.849
Average annual consumption per insured consumer (in DDD)		225
Percentage insured consumers with more than 3 times the average consumption		0,47%
Coefficient of variation ³ (2013-2015)		32,98%
Coefficient of variation ³ (2021-2023)		30,41%
Trend ⁴ (2013-2023)		-1,55%
Trend ⁵ (2013-2021)		-1,53%
Trend ⁵ (2021-2023)		-1,67%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		10.205.346€
Average annual expenditure per insured		0,89€
Average patient share per insured consumer		22,6%
Max/Min Ratio ² of expenditure per insured (by district*)		2,52
Percentage low-cost medication		55,5%
Trend (2013-2023)		-0,45%
Trend (2021-2023)		-0,30%

Link to the report: [RAPPORT-EN-Medicat. cardio-vasc. Antiarythmiques classe I et III 2023.pdf](#)

Medication use – SUMMARY

Lipid-modifying agents

Main prescribers:	<i>General practitioners</i>	81%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		2,5%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		17,14%
Median age		69 y.
Max/min ratio ² of the median age (by district*)		1,04
Percentage of women		47,5%
Ratio Preferential rate/General rate		1,16
Coefficient of variation (2023)		9,7%
Max/min ratio ² of percentage of insured consumers (by district*)		1,54
CONSUMPTION		
Annual consumption (DDD)		764.663.346
Consumption of DDD (per 100.000 insured persons)		6.637.412
Average annual consumption per insured consumer (in DDD)		387
Percentage insured consumers with more than 3 times the average consumption		3,88%
Coefficient of variation ³ (2013-2015)		11,18%
Coefficient of variation ³ (2021-2023)		13,01% NS
Trend ⁴ (2013-2023)		2,59% ***
Trend ⁵ (2013-2021)		1,82% ***
Trend ⁵ (2021-2023)		5,74% ***
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		187.504.974€
Average annual expenditure per insured		16,28€
Average patient share per insured consumer		17,5%
Max/Min Ratio ² of expenditure per insured (by district*)		1,57
Percentage low-cost medication		97,9%
Trend (2013-2023)		-1,72%
Trend (2021-2023)		24,38%

Link to the report: [RAPPORT-EN-Medcat_Cardio-vasc_Hypolipidemants_2023.pdf](#)

5. SYSTEMIC HORMONAL PREPARATIONS

Levothyroxine (Thyroid hormone)

Main prescribers:	General practitioners	75%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		0,0%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	5,85%	
Median age	63 y.	
Max/min ratio ² of the median age (by district*)	1,05	
Percentage of women	81,8%	
Ratio Preferential rate/General rate	1,21	
Coefficient of variation (2023)	42,2%	
Max/min ratio ² of percentage of insured consumers (by district*)	3,47	
CONSUMPTION		
Annual consumption (DDD)	129.139.119	
Consumption of DDD (per 100.000 insured persons)	1.120.950	
Average annual consumption per insured consumer (in DDD)	192	
Percentage insured consumers with more than 3 times the average consumption	1,11%	
Coefficient of variation ³ (2013-2015)	46,35%	NS
Coefficient of variation ³ (2021-2023)	41%	NS
Trend ⁴ (2013-2023)	0,53%	NS
Trend ⁵ (2013-2021)	0,62%	NS
Trend ⁵ (2021-2023)	0,18%	NS
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	16.524.360€	
Average annual expenditure per insured	1,43€	
Average patient share per insured consumer	13,1%	
Max/Min Ratio ² of expenditure per insured (by district*)	3,16	
Percentage low-cost medication	NA	
Trend (2013-2023)	1,93%	
Trend (2021-2023)	3,13%	

Link to the report: [RAPPORT-EN-Levothyroxine_hormone_thyroidienne_2023.pdf](#)

6. ANTIINFECTIVES FOR SYSTEMIC USE

Antibiotics - All prescribers

Main prescribers:	<i>General practitioners</i>	68%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		12,4%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		35,53%
Median age		45 y.
Max/min ratio ² of the median age (by district*)		1,09
Percentage of women		56,9%
Ratio Preferential rate/General rate		1,11
Coefficient of variation (2023)		11,0%
Max/min ratio ² of percentage of insured consumers (by district*)		1,48
CONSUMPTION		
Annual consumption (DDD)		82.772.795
Consumption of DDD (per 100.000 insured persons)		718.482
Average annual consumption per insured consumer (in DDD)		20
Percentage insured consumers with more than 3 times the average consumption		4,06%
Coefficient of variation ³ (2013-2015)		8,64%
Coefficient of variation ³ (2021-2023)		10,04%
Trend ⁴ (2013-2023)		-2,13%
Trend ⁵ (2013-2021)		-5,23%
Trend ⁵ (2021-2023)		11,33%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		66.481.761€
Average annual expenditure per insured		5,77€
Average patient share per insured consumer		37,7%
Max/Min Ratio ² of expenditure per insured (by district*)		1,67
Percentage low-cost medication		83,5%
Trend (2013-2023)		-5,78%
Trend (2021-2023)		13,77%

Link to the report: [RAPPORT-EN-Antibiotiques_Tous_prescripteurs_2023.pdf](#)

Medication use – SUMMARY

Antibiotics (Amoxicillin) - All prescribers

Main prescribers:	General practitioners	67%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	8,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	23,08%	
Median age	42 y.	
Max/min ratio ² of the median age (by district*)	1,18	
Percentage of women	53,3%	
Ratio Preferential rate/General rate	1,18	
Coefficient of variation (2023)	12,3%	
Max/min ratio ² of percentage of insured consumers (by district*)	1,59	
CONSUMPTION		
Annual consumption (DDD)	41.799.562	
Consumption of DDD (per 100.000 insured persons)	362.828	
Average annual consumption per insured consumer (in DDD)	16	
Percentage insured consumers with more than 3 times the average consumption	1,97%	
Coefficient of variation ³ (2013-2015)	9,72%	NS
Coefficient of variation ³ (2021-2023)	13,26%	
Trend ⁴ (2013-2023)	-1,13%	***
Trend ⁵ (2013-2021)	-5,53%	***
Trend ⁵ (2021-2023)	18,58%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	30.337.159€	
Average annual expenditure per insured	2,63€	
Average patient share per insured consumer	38,2%	
Max/Min Ratio ² of expenditure per insured (by district*)	1,74	
Percentage low-cost medication	100,0%	
Trend (2013-2023)	-4,40%	
Trend (2021-2023)	20,33%	

Link to the report: [RAPPORT-EN-Antibiotiques_Amoxicilline_Tous_prescripteurs_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - General medicine

Main prescribers:	10004 - Accredited general practitioners + ECG	75%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	28,36%	
Median age	46 y.	
Max/min ratio ² of the median age (by district*)	1,07	
Percentage of women	58,3%	
Ratio Preferential rate/General rate	1,11	
Coefficient of variation (2023)	14,2%	
Max/min ratio ² of percentage of insured consumers (by district*)	1,78	
CONSUMPTION		
Annual consumption (DDD)	60.905.475	
Consumption of DDD (per 100.000 insured persons)	528.670	
Average annual consumption per insured consumer (in DDD)	19	
Percentage insured consumers with more than 3 times the average consumption	3,73%	
Coefficient of variation ³ (2013-2015)	12,06%	NS
Coefficient of variation ³ (2021-2023)	13,58%	
Trend ⁴ (2013-2023)	-2,55%	***
Trend ⁵ (2013-2021)	-6,33%	***
Trend ⁵ (2021-2023)	14,18%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	46.315.502€	
Average annual expenditure per insured	4,02€	
Average patient share per insured consumer	38,9%	
Max/Min Ratio ² of expenditure per insured (by district*)	1,97	
Percentage low-cost medication	84,0%	
Trend (2013-2023)	-6,35%	
Trend (2021-2023)	18,14%	

Link to the report: [RAPPORT-EN-Antibiotiques_Medecine_generale_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Paediatrics

Main prescribers:	10690 - Specialists in paediatrics	80%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	1,40%	
Median age	3 y.	
Max/min ratio ² of the median age (by district*)	1,33	
Percentage of women	48,7%	
Ratio Preferential rate/General rate	0,8	
Coefficient of variation (2023)	26,9%	
Max/min ratio ² of percentage of insured consumers (by district*)	4,2	
CONSUMPTION		
Annual consumption (DDD)	1.738.999	
Consumption of DDD (per 100.000 insured persons)	15.095	
Average annual consumption per insured consumer (in DDD)	11	
Percentage insured consumers with more than 3 times the average consumption	3,82%	
Coefficient of variation ³ (2013-2015)	23,28%	
Coefficient of variation ³ (2021-2023)	27,92%	NS
Trend ⁴ (2013-2023)	-0,53%	**
Trend ⁵ (2013-2021)	-3,91%	***
Trend ⁵ (2021-2023)	14,20%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	3.025.569€	
Average annual expenditure per insured	0,26€	
Average patient share per insured consumer	22,2%	
Max/Min Ratio ² of expenditure per insured (by district*)	3,15	
Percentage low-cost medication	95,4%	
Trend (2013-2023)	-6,11%	
Trend (2021-2023)	7,01%	

Link to the report: [RAPPORT-EN-Antibiotiques_Pediatrie_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Gynaecology

Main prescribers:	10340 - Specialists in gynaecology-obstetrics	80%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,69%	
Median age	35 y.	
Max/min ratio ² of the median age (by district*)	1,09	
Percentage of women	97,0%	
Ratio Preferential rate/General rate	1,1	
Coefficient of variation (2023)	25,4%	
Max/min ratio ² of percentage of insured consumers (by district*)	2,86	
CONSUMPTION		
Annual consumption (DDD)	873.789	
Consumption of DDD (per 100.000 insured persons)	7.585	
Average annual consumption per insured consumer (in DDD)	11	
Percentage insured consumers with more than 3 times the average consumption	3,95%	
Coefficient of variation ³ (2013-2015)	24,23%	NS
Coefficient of variation ³ (2021-2023)	24,6%	
Trend ⁴ (2013-2023)	-2,03%	***
Trend ⁵ (2013-2021)	-2,72%	***
Trend ⁵ (2021-2023)	0,77%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	814.079€	
Average annual expenditure per insured	0,07€	
Average patient share per insured consumer	35,9%	
Max/Min Ratio ² of expenditure per insured (by district*)	2,67	
Percentage low-cost medication	66,8%	
Trend (2013-2023)	-4,32%	
Trend (2021-2023)	5,09%	

Link to the report: [RAPPORT-EN-Antibiotiques_Gynecologie_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Internal medicine

Main prescribers:	<i>10580 - Specialists in internal medicine</i>	91%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,18%	
Median age	48 y.	
Max/min ratio ² of the median age (by district*)	1,4	
Percentage of women	49,9%	
Ratio Preferential rate/General rate	1,51	
Coefficient of variation (2023)	60,3%	
Max/min ratio ² of percentage of insured consumers (by district*)	15,47	
CONSUMPTION		
Annual consumption (DDD)	503.092	
Consumption of DDD (per 100.000 insured persons)	4.367	
Average annual consumption per insured consumer (in DDD)	24	
Percentage insured consumers with more than 3 times the average consumption	6,09%	
Coefficient of variation ³ (2013-2015)	30,46%	NS
Coefficient of variation ³ (2021-2023)	53,77%	
Trend ⁴ (2013-2023)	-5,95%	***
Trend ⁵ (2013-2021)	-6,05%	NS
Trend ⁵ (2021-2023)	-5,56%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	527.200€	
Average annual expenditure per insured	0,05€	
Average patient share per insured consumer	29,0%	
Max/Min Ratio ² of expenditure per insured (by district*)	11,22	
Percentage low-cost medication	92,5%	
Trend (2013-2023)	-7,90%	
Trend (2021-2023)	1,40%	

Link to the report: [RAPPORT-EN-Antibiotiques_Medecine_interne_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Gastroenterology

Main prescribers:	10650 - Specialists in gastroenterology	63%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,20%	
Median age	56 y.	
Max/min ratio ² of the median age (by district*)	1,33	
Percentage of women	53,2%	
Ratio Preferential rate/General rate	1,5	
Coefficient of variation (2023)	27,4%	
Max/min ratio ² of percentage of insured consumers (by district*)	2,91	
CONSUMPTION		
Annual consumption (DDD)	546.323	
Consumption of DDD (per 100.000 insured persons)	4.742	
Average annual consumption per insured consumer (in DDD)	24	
Percentage insured consumers with more than 3 times the average consumption	2,72%	
Coefficient of variation ³ (2013-2015)	33,64%	NS
Coefficient of variation ³ (2021-2023)	34,77%	
Trend ⁴ (2013-2023)	-1,83%	***
Trend ⁵ (2013-2021)	-3,29%	**
Trend ⁵ (2021-2023)	4,25%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	361.287€	
Average annual expenditure per insured	0,03€	
Average patient share per insured consumer	41,3%	
Max/Min Ratio ² of expenditure per insured (by district*)	3,64	
Percentage low-cost medication	92,2%	
Trend (2013-2023)	-6,13%	
Trend (2021-2023)	7,03%	

Link to the report: [RAPPORT-EN-Antibiotiques_Gastroenterologie_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Pneumology

Main prescribers:	10620 - Specialists in pneumology	59%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,33%	
Median age	65 y.	
Max/min ratio ² of the median age (by district*)	1,15	
Percentage of women	51,8%	
Ratio Preferential rate/General rate	1,8	
Coefficient of variation (2023)	24,6%	
Max/min ratio ² of percentage of insured consumers (by district*)	2,46	
CONSUMPTION		
Annual consumption (DDD)	1.327.604	
Consumption of DDD (per 100.000 insured persons)	11.524	
Average annual consumption per insured consumer (in DDD)	35	
Percentage insured consumers with more than 3 times the average consumption	7,05%	
Coefficient of variation ³ (2013-2015)	29,32%	NS
Coefficient of variation ³ (2021-2023)	31,59%	
Trend ⁴ (2013-2023)	2,88%	**
Trend ⁵ (2013-2021)	1,46%	NS
Trend ⁵ (2021-2023)	8,76%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	2.044.351€	
Average annual expenditure per insured	0,18€	
Average patient share per insured consumer	22,7%	
Max/Min Ratio ² of expenditure per insured (by district*)	3,85	
Percentage low-cost medication	78,6%	
Trend (2013-2023)	0,13%	
Trend (2021-2023)	-7,43%	

Link to the report: [RAPPORT-EN-Antibiotiques_Pneumologie_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Surgery

Main prescribers:	10140 - Specialists in surgery	88%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,27%	
Median age	52 y.	
Max/min ratio ² of the median age (by district*)	1,2	
Percentage of women	47,6%	
Ratio Preferential rate/General rate	1,36	
Coefficient of variation (2023)	27,2%	
Max/min ratio ² of percentage of insured consumers (by district*)	2,58	
CONSUMPTION		
Annual consumption (DDD)	496.815	
Consumption of DDD (per 100.000 insured persons)	4.312	
Average annual consumption per insured consumer (in DDD)	16	
Percentage insured consumers with more than 3 times the average consumption	3,46%	
Coefficient of variation ³ (2013-2015)	34,52%	NS
Coefficient of variation ³ (2021-2023)	31,76%	
Trend ⁴ (2013-2023)	-2,68%	***
Trend ⁵ (2013-2021)	-4,55%	***
Trend ⁵ (2021-2023)	5,17%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	396.735€	
Average annual expenditure per insured	0,03€	
Average patient share per insured consumer	41,7%	
Max/Min Ratio ² of expenditure per insured (by district*)	3,06	
Percentage low-cost medication	94,5%	
Trend (2013-2023)	-6,58%	
Trend (2021-2023)	8,15%	

Link to the report: [RAPPORT-EN-Antibiotiques_Chirurgie_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Urology

Main prescribers:	10450 - Specialists in urology	78%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,60%	
Median age	66 y.	
Max/min ratio ² of the median age (by district*)	1,11	
Percentage of women	39,4%	
Ratio Preferential rate/General rate	1,23	
Coefficient of variation (2023)	23,6%	
Max/min ratio ² of percentage of insured consumers (by district*)	2,5	
CONSUMPTION		
Annual consumption (DDD)	1.079.739	
Consumption of DDD (per 100.000 insured persons)	9.372	
Average annual consumption per insured consumer (in DDD)	16	
Percentage insured consumers with more than 3 times the average consumption	6,04%	
Coefficient of variation ³ (2013-2015)	25,66%	
Coefficient of variation ³ (2021-2023)	30,64%	NS
Trend ⁴ (2013-2023)	-6,40%	***
Trend ⁵ (2013-2021)	-7,10%	**
Trend ⁵ (2021-2023)	-3,51%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	1.035.738€	
Average annual expenditure per insured	0,09€	
Average patient share per insured consumer	35,8%	
Max/Min Ratio ² of expenditure per insured (by district*)	3,08	
Percentage low-cost medication	58,6%	
Trend (2013-2023)	-5,87%	
Trend (2021-2023)	6,82%	

Link to the report: [RAPPORT-EN-Antibiotiques_Urologie_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Plastic surgery

Main prescribers:	10210 - Specialists in plastic surgery	75%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,14%	
Median age	48 y.	
Max/min ratio ² of the median age (by district*)	1,33	
Percentage of women	76,4%	
Ratio Preferential rate/General rate	0,89	
Coefficient of variation (2023)	26,0%	
Max/min ratio ² of percentage of insured consumers (by district*)	2,69	
CONSUMPTION		
Annual consumption (DDD)	197.932	
Consumption of DDD (per 100.000 insured persons)	1.718	
Average annual consumption per insured consumer (in DDD)	12	
Percentage insured consumers with more than 3 times the average consumption	2,50%	
Coefficient of variation ³ (2013-2015)	36,58%	NS
Coefficient of variation ³ (2021-2023)	23,14%	
Trend ⁴ (2013-2023)	1,64%	NS
Trend ⁵ (2013-2021)	0,02%	
Trend ⁵ (2021-2023)	8,41%	***
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	161.979€	
Average annual expenditure per insured	0,01€	
Average patient share per insured consumer	41,2%	
Max/Min Ratio ² of expenditure per insured (by district*)	2,54	
Percentage low-cost medication	93,0%	
Trend (2013-2023)	-2,73%	
Trend (2021-2023)	8,20%	

Link to the report: [RAPPORT-EN-Antibiotiques_Chirurgie_plastique_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Dentistry

Main prescribers:	30001 - Dental science graduates - general dentist	95%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	3,91%	
Median age	49 y.	
Max/min ratio ² of the median age (by district*)	1,13	
Percentage of women	52,5%	
Ratio Preferential rate/General rate	1,37	
Coefficient of variation (2023)	27,4%	
Max/min ratio ² of percentage of insured consumers (by district*)	2,87	
CONSUMPTION		
Annual consumption (DDD)	4.937.933	
Consumption of DDD (per 100.000 insured persons)	42.862	
Average annual consumption per insured consumer (in DDD)	11	
Percentage insured consumers with more than 3 times the average consumption	1,94%	
Coefficient of variation ³ (2013-2015)	20,83%	NS
Coefficient of variation ³ (2021-2023)	27,65%	NS
Trend ⁴ (2013-2023)	0,46%	NS
Trend ⁵ (2013-2021)	-0,05%	***
Trend ⁵ (2021-2023)	2,55%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	4.086.713€	
Average annual expenditure per insured	0,35€	
Average patient share per insured consumer	36,5%	
Max/Min Ratio ² of expenditure per insured (by district*)	3,07	
Percentage low-cost medication	99,4%	
Trend (2013-2023)	-3,89%	
Trend (2021-2023)	3,94%	

Link to the report: [RAPPORT-EN-Antibiotiques_Dentistes_2023.pdf](#)

Medication use – SUMMARY

Antibiotics - Periodontology

Main prescribers:	30006 - Dentists specialised in periodontology	94%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹	12,4%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,24%	
Median age	57 y.	
Max/min ratio ² of the median age (by district*)	1,07	
Percentage of women	56,2%	
Ratio Preferential rate/General rate	0,42	
Coefficient of variation (2023)	43,6%	
Max/min ratio ² of percentage of insured consumers (by district*)	6,04	
CONSUMPTION		
Annual consumption (DDD)	252.140	
Consumption of DDD (per 100.000 insured persons)	2.189	
Average annual consumption per insured consumer (in DDD)	9	
Percentage insured consumers with more than 3 times the average consumption	1,47%	
Coefficient of variation ³ (2013-2015)	45,39%	NS
Coefficient of variation ³ (2021-2023)	46,88%	***
Trend ⁴ (2013-2023)	8,13%	
Trend ⁵ (2013-2021)	9,18%	NS
Trend ⁵ (2021-2023)	4,01%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	218.734€	
Average annual expenditure per insured	0,02€	
Average patient share per insured consumer	33,7%	
Max/Min Ratio ² of expenditure per insured (by district*)	6,48	
Percentage low-cost medication	99,8%	
Trend (2013-2023)	4,04%	
Trend (2021-2023)	6,83%	

Link to the report: [RAPPORT-EN-Antibiotiques_Parodontologues_2023.pdf](#)

7. MUSCULO-SKELETAL SYSTEM

Antigout preparations

Main prescribers:	General practitioners	84%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		1,8%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	2,97%	
Median age	70 y.	
Max/min ratio ² of the median age (by district*)	1,07	
Percentage of women	25,6%	
Ratio Preferential rate/General rate	1,12	
Coefficient of variation (2023)	18,1%	
Max/min ratio ² of percentage of insured consumers (by district*)	2,16	
CONSUMPTION		
Annual consumption (DDD)	52.947.418	
Consumption of DDD (per 100.000 insured persons)	459.593	
Average annual consumption per insured consumer (in DDD)	155	
Percentage insured consumers with more than 3 times the average consumption	1,15%	
Coefficient of variation ³ (2013-2015)	17,82%	NS
Coefficient of variation ³ (2021-2023)	17%	
Trend ⁴ (2013-2023)	1,55%	***
Trend ⁵ (2013-2021)	1,63%	***
Trend ⁵ (2021-2023)	1,24%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	9.486.029€	
Average annual expenditure per insured	0,82€	
Average patient share per insured consumer	15,5%	
Max/Min Ratio ² of expenditure per insured (by district*)	2,04	
Percentage low-cost medication	91,5%	
Trend (2013-2023)	2,27%	
Trend (2021-2023)	4,25%	

Link to the report: [RAPPORT-EN-Antigoutteux_2023.pdf](#)

Medication use – SUMMARY

Drugs affecting bone structure and mineralization

Main prescribers:	<i>General practitioners</i>	64%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		1,9%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		1,29%
Median age		74 y.
Max/min ratio ² of the median age (by district*)		1,07
Percentage of women		87,3%
Ratio Preferential rate/General rate		1,2
Coefficient of variation (2023)		25,8%
Max/min ratio ² of percentage of insured consumers (by district*)		2,34
CONSUMPTION		
Annual consumption (DDD)		58.991.137
Consumption of DDD (per 100.000 insured persons)		512.053
Average annual consumption per insured consumer (in DDD)		397
Percentage insured consumers with more than 3 times the average consumption		4,17%
Coefficient of variation ³ (2013-2015)		14,71%
Coefficient of variation ³ (2021-2023)		26,89% NS
Trend ⁴ (2013-2023)		-0,75% *
Trend ⁵ (2013-2021)		-1,02% NS
Trend ⁵ (2021-2023)		0,34%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		45.999.876€
Average annual expenditure per insured		3,99€
Average patient share per insured consumer		5,9%
Max/Min Ratio ² of expenditure per insured (by district*)		2,94
Percentage low-cost medication		33,8%
Trend (2013-2023)		-0,34%
Trend (2021-2023)		7,93%

Link to the report:

[RAPPORT-EN-Preparations affectant la structure et la mineralisation de los 2023.pdf](#)

Medication use – SUMMARY

Non-steroidal anti-inflammatory drugs (NSAID)

Main prescribers:	<i>General practitioners</i>	72%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		32,7%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		23,65%
Median age		50 y.
Max/min ratio ² of the median age (by district*)		1,06
Percentage of women		54,8%
Ratio Preferential rate/General rate		1,07
Coefficient of variation (2023)		11,2%
Max/min ratio ² of percentage of insured consumers (by district*)		1,58
CONSUMPTION		
Annual consumption (DDD)		129.982.414
Consumption of DDD (per 100.000 insured persons)		1.128.270
Average annual consumption per insured consumer (in DDD)		48
Percentage insured consumers with more than 3 times the average consumption		4,87%
Coefficient of variation ³ (2013-2015)	9,79%	NS
Coefficient of variation ³ (2021-2023)	17,81%	
Trend ⁴ (2013-2023)	-2,25%	***
Trend ⁵ (2013-2021)	-2,97%	***
Trend ⁵ (2021-2023)	0,66%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		37.655.968€
Average annual expenditure per insured		3,27€
Average patient share per insured consumer		13,3%
Max/Min Ratio ² of expenditure per insured (by district*)		1,85
Percentage low-cost medication		87,0%
Trend (2013-2023)	-3,84%	
Trend (2021-2023)	2,54%	

Link to the report: [RAPPORT-EN-Anti-inflammatoires_non_steroidiensAINS_2023.pdf](#)

8. NERVOUS SYSTEM

Antidepressants

Main prescribers:	General practitioners	74%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		0,7%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	11,58%	
Median age	58 y.	
Max/min ratio ² of the median age (by district*)	1,05	
Percentage of women	65,8%	
Ratio Preferential rate/General rate	1,69	
Coefficient of variation (2023)	11,4%	
Max/min ratio ² of percentage of insured consumers (by district*)	1,6	
CONSUMPTION		
Annual consumption (DDD)	384.006.320	
Consumption of DDD (per 100.000 insured persons)	3.333.242	
Average annual consumption per insured consumer (in DDD)	288	
Percentage insured consumers with more than 3 times the average consumption	4,02%	
Coefficient of variation ³ (2013-2015)	16,87%	NS
Coefficient of variation ³ (2021-2023)	13,15%	
Trend ⁴ (2013-2023)	1,99%	***
Trend ⁵ (2013-2021)	2,03%	NS
Trend ⁵ (2021-2023)	1,82%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	88.648.015€	
Average annual expenditure per insured	7,69€	
Average patient share per insured consumer	21,5%	
Max/Min Ratio ² of expenditure per insured (by district*)	1,64	
Percentage low-cost medication	95,8%	
Trend (2013-2023)	-4,48%	
Trend (2021-2023)	1,93%	

Link to the report: [RAPPORT-EN-Antidepresseurs_2023.pdf](#)

Medication use – SUMMARY

Antipsychotics

Main prescribers:	<i>General practitioners</i>	57%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		1,9%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		3,26%
Median age		57 y.
Max/min ratio ² of the median age (by district*)		1,13
Percentage of women		55,0%
Ratio Preferential rate/General rate		3,62
Coefficient of variation (2023)		12,9%
Max/min ratio ² of percentage of insured consumers (by district*)		1,53
CONSUMPTION		
Annual consumption (DDD)		56.748.613
Consumption of DDD (per 100.000 insured persons)		492.588
Average annual consumption per insured consumer (in DDD)		151
Percentage insured consumers with more than 3 times the average consumption		8,19%
Coefficient of variation ³ (2013-2015)		14,92%
Coefficient of variation ³ (2021-2023)		14,97%
Trend ⁴ (2013-2023)		0,38%
Trend ⁵ (2013-2021)		0,97%
Trend ⁵ (2021-2023)		-1,92%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		81.961.596€
Average annual expenditure per insured		7,11€
Average patient share per insured consumer		11,5%
Max/Min Ratio ² of expenditure per insured (by district*)		2,04
Percentage low-cost medication		71,3%
Trend (2013-2023)		-3,54%
Trend (2021-2023)		-2,47%

Link to the report: [RAPPORT-EN-Antipsychotiques_2023.pdf](#)

Medication use – SUMMARY

Antivertigo preparations

Main prescribers:	<i>General practitioners</i>	84%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		10,5%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		1,54%
Median age		69 y.
Max/min ratio ² of the median age (by district*)		1,21
Percentage of women		69,5%
Ratio Preferential rate/General rate		1,39
Coefficient of variation (2023)		21,8%
Max/min ratio ² of percentage of insured consumers (by district*)		1,91
CONSUMPTION		
Annual consumption (DDD)		34.399.545
Consumption of DDD (per 100.000 insured persons)		298.594
Average annual consumption per insured consumer (in DDD)		194
Percentage insured consumers with more than 3 times the average consumption		7,50%
Coefficient of variation ³ (2013-2015)		28,08%
Coefficient of variation ³ (2021-2023)		30,17% NS
Trend ⁴ (2013-2023)		-1,61% ***
Trend ⁵ (2013-2021)		-0,48% ***
Trend ⁵ (2021-2023)		-6,02%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		2.613.452€
Average annual expenditure per insured		0,23€
Average patient share per insured consumer		63,1%
Max/Min Ratio ² of expenditure per insured (by district*)		3,08
Percentage low-cost medication		39,4%
Trend (2013-2023)		-0,93%
Trend (2021-2023)		4,32%

Link to the report: [RAPPORT-EN-Preparations_antivertigineuses_2023.pdf](#)

Medication use – SUMMARY

Dopaminergic agents (anti-parkinson drug)

Main prescribers:	<i>General practitioners</i>	59%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		2,8%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		0,70%
Median age		75 y.
Max/min ratio ² of the median age (by district*)		1,08
Percentage of women		55,0%
Ratio Preferential rate/General rate		1,5
Coefficient of variation (2023)		16,1%
Max/min ratio ² of percentage of insured consumers (by district*)		2,22
CONSUMPTION		
Annual consumption (DDD)		18.911.765
Consumption of DDD (per 100.000 insured persons)		164.157
Average annual consumption per insured consumer (in DDD)		235
Percentage insured consumers with more than 3 times the average consumption		8,85%
Coefficient of variation ³ (2013-2015)		17,3%
Coefficient of variation ³ (2021-2023)		16,8% NS
Trend ⁴ (2013-2023)		0,21% NS
Trend ⁵ (2013-2021)		0,35% ***
Trend ⁵ (2021-2023)		-0,36%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		22.027.507€
Average annual expenditure per insured		1,91€
Average patient share per insured consumer		17,0%
Max/Min Ratio ² of expenditure per insured (by district*)		1,85
Percentage low-cost medication		89,2%
Trend (2013-2023)		-3,36%
Trend (2021-2023)		-0,12%

Link to the report: [RAPPORT-EN-Agents dopaminergiques antiparkinsoniens 2023.pdf](#)

Medication use – SUMMARY

Gabapentinoids

Main prescribers:	<i>General practitioners</i>	72%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		5,1%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		1,80%
Median age		64 y.
Max/min ratio ² of the median age (by district*)		1,1
Percentage of women		60,5%
Ratio Preferential rate/General rate		2,4
Coefficient of variation (2023)		20,0%
Max/min ratio ² of percentage of insured consumers (by district*)		2,21
CONSUMPTION		
Annual consumption (DDD)		28.901.060
Consumption of DDD (per 100.000 insured persons)		250.866
Average annual consumption per insured consumer (in DDD)		139
Percentage insured consumers with more than 3 times the average consumption		7,04%
Coefficient of variation ³ (2013-2015)		20,09%
Coefficient of variation ³ (2021-2023)		17,51% NS
Trend ⁴ (2013-2023)		9,56% ***
Trend ⁵ (2013-2021)		11,50% ***
Trend ⁵ (2021-2023)		2,14%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		18.196.262€
Average annual expenditure per insured		1,58€
Average patient share per insured consumer		18,9%
Max/Min Ratio ² of expenditure per insured (by district*)		1,91
Percentage low-cost medication		100,0%
Trend (2013-2023)		-2,09%
Trend (2021-2023)		1,79%

Link to the report: [RAPPORT-EN-Gabapentinoides_2023.pdf](#)

Medication use – SUMMARY

Methylphenidate

Main prescribers:	Psychiatry	44%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		NA
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	2,18%	
Median age	13 y.	
Max/min ratio ² of the median age (by district*)	1,08	
Percentage of women	26,4%	
Ratio Preferential rate/General rate	0,77	
Coefficient of variation (2023)	53,1%	
Max/min ratio ² of percentage of insured consumers (by district*)	7,44	
CONSUMPTION		
Annual consumption (DDD)	5.741.119	
Consumption of DDD (per 100.000 insured persons)	361.665	
Average annual consumption per insured consumer (in DDD)	166	
Percentage insured consumers with more than 3 times the average consumption	3,35%	
Coefficient of variation ³ (2013-2015)	60,82%	NS
Coefficient of variation ³ (2021-2023)	62,98%	
Trend ⁴ (2013-2023)	1,82%	***
Trend ⁵ (2013-2021)	2,09%	*
Trend ⁵ (2021-2023)	0,73%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	5.129.270€	
Average annual expenditure per insured	3,23€	
Average patient share per insured consumer	20,2%	
Max/Min Ratio ² of expenditure per insured (by district*)	12,96	
Percentage low-cost medication	NA	
Trend (2013-2023)	-0,86%	
Trend (2021-2023)	2,00%	

Link to the report: [RAPPORT-EN-Methylphenidate_6-17_2023.pdf](#)

Medication use – SUMMARY

Opioids

Main prescribers:	<i>General practitioners</i>	79%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		19,1%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		9,79%
Median age		59 y.
Max/min ratio ² of the median age (by district*)		1,05
Percentage of women		57,7%
Ratio Preferential rate/General rate		1,68
Coefficient of variation (2023)		17,6%
Max/min ratio ² of percentage of insured consumers (by district*)		1,71
CONSUMPTION		
Annual consumption (DDD)		64.346.658
Consumption of DDD (per 100.000 insured persons)		558.540
Average annual consumption per insured consumer (in DDD)		57
Percentage insured consumers with more than 3 times the average consumption		8,72%
Coefficient of variation ³ (2013-2015)		20,74%
Coefficient of variation ³ (2021-2023)		15,83%
Trend ⁴ (2013-2023)		-0,50%
Trend ⁵ (2013-2021)		0,92%
Trend ⁵ (2021-2023)		-5,99%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		54.938.741€
Average annual expenditure per insured		4,77€
Average patient share per insured consumer		21,6%
Max/Min Ratio ² of expenditure per insured (by district*)		1,53
Percentage low-cost medication		96,7%
Trend (2013-2023)		-1,94%
Trend (2021-2023)		-3,16%

Link to the report: [RAPPORT-EN-Opiaces_2023.pdf](#)

Medication use – SUMMARY

Antimigraine preparation

Main prescribers:	<i>Neurology</i>	56%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		45,9%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		0,34%
Median age		45 y.
Max/min ratio ² of the median age (by district*)		1,14
Percentage of women		81,9%
Ratio Preferential rate/General rate		1,07
Coefficient of variation (2023)		30,1%
Max/min ratio ² of percentage of insured consumers (by district*)		2,91
CONSUMPTION		
Annual consumption (DDD)		6.512.864
Consumption of DDD (per 100.000 insured persons)		56.533
Average annual consumption per insured consumer (in DDD)		165
Percentage insured consumers with more than 3 times the average consumption		9,81%
Coefficient of variation ³ (2013-2015)		26,52%
Coefficient of variation ³ (2021-2023)		31,13%
Trend ⁴ (2013-2023)		28,71%
Trend ⁵ (2013-2021)		25,40%
Trend ⁵ (2021-2023)		42,83%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		49.047.665€
Average annual expenditure per insured		4,26€
Average patient share per insured consumer		3,4%
Max/Min Ratio ² of expenditure per insured (by district*)		3,62
Percentage low-cost medication		38,2%
Trend (2013-2023)		41,90%
Trend (2021-2023)		89,43%

Link to the report: [RAPPORT-EN-Antimigraineux_2023.pdf](#)

9. RESPIRATORY SYSTEM

Antihistamines for systemic use

Main prescribers:	<i>General practitioners</i>	81%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		28,0%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	4,58%	
Median age	50 y.	
Max/min ratio ² of the median age (by district*)	1,13	
Percentage of women	59,9%	
Ratio Preferential rate/General rate	1,16	
Coefficient of variation (2023)	28,3%	
Max/min ratio ² of percentage of insured consumers (by district*)	2,67	
CONSUMPTION		
Annual consumption (DDD)	62.050.270	
Consumption of DDD (per 100.000 insured persons)	538.607	
Average annual consumption per insured consumer (in DDD)	118	
Percentage insured consumers with more than 3 times the average consumption	7,92%	
Coefficient of variation ³ (2013-2015)	13,08%	NS
Coefficient of variation ³ (2021-2023)	17,37%	
Trend ⁴ (2013-2023)	-0,72%	**
Trend ⁵ (2013-2021)	-0,79%	NS
Trend ⁵ (2021-2023)	-0,44%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	5.725.344€	
Average annual expenditure per insured	0,5€	
Average patient share per insured consumer	46,6%	
Max/Min Ratio ² of expenditure per insured (by district*)	2,25	
Percentage low-cost medication	100,0%	
Trend (2013-2023)	-2,83%	
Trend (2021-2023)	3,12%	

Link to the report: [RAPPORT-EN-Antihistaminiques_a_usage_systemique_2023.pdf](#)

Medication use – SUMMARY

Drugs for obstructive airway diseases

Main prescribers:	<i>General practitioners</i>	73%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		3,2%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		15,73%
Median age		48 y.
Max/min ratio ² of the median age (by district*)		1,26
Percentage of women		53,8%
Ratio Preferential rate/General rate		1,17
Coefficient of variation (2023)		17,9%
Max/min ratio ² of percentage of insured consumers (by district*)		1,87
CONSUMPTION		
Annual consumption (DDD)		247.574.990
Consumption of DDD (per 100.000 insured persons)		2.148.994
Average annual consumption per insured consumer (in DDD)		137
Percentage insured consumers with more than 3 times the average consumption		7,67%
Coefficient of variation ³ (2013-2015)		10,7%
Coefficient of variation ³ (2021-2023)		13,58%
Trend ⁴ (2013-2023)		-0,33%
Trend ⁵ (2013-2021)		-1,10%
Trend ⁵ (2021-2023)		2,81%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		262.252.036€
Average annual expenditure per insured		22,76€
Average patient share per insured consumer		11,8%
Max/Min Ratio ² of expenditure per insured (by district*)		1,4
Percentage low-cost medication		43,5%
Trend (2013-2023)		2,74%
Trend (2021-2023)		8,74%

Link to the report: [RAPPORT-EN-Medic. affections respiratoires obstructives 2023.pdf](#)

10. SENSORY ORGANS

Antiglaucoma preparations and miotics

Main prescribers:	<i>Ophthalmological surgery</i>	78%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		6,1%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		2,18%
Median age		73 y.
Max/min ratio ² of the median age (by district*)		1,04
Percentage of women		53,6%
Ratio Preferential rate/General rate		0,99
Coefficient of variation (2023)		14,0%
Max/min ratio ² of percentage of insured consumers (by district*)		1,83
CONSUMPTION		
Annual consumption (DDD)		103.230.156
Consumption of DDD (per 100.000 insured persons)		896.056
Average annual consumption per insured consumer (in DDD)		411
Percentage insured consumers with more than 3 times the average consumption		4,69%
Coefficient of variation ³ (2013-2015)		15,47%
Coefficient of variation ³ (2021-2023)		14,64%
Trend ⁴ (2013-2023)		4,79%
Trend ⁵ (2013-2021)		5,18%
Trend ⁵ (2021-2023)		3,22%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		20.595.220€
Average annual expenditure per insured		1,79€
Average patient share per insured consumer		22,0%
Max/Min Ratio ² of expenditure per insured (by district*)		1,73
Percentage low-cost medication		83,5%
Trend (2013-2023)		-1,45%
Trend (2021-2023)		2,32%

Link to the report: [RAPPORT-EN-Myotiques et préparations contre le glaucome 2023.pdf](#)

11. IMMUNITY

Vaccination against influenza (65+/excl. nursing homes)

Main prescribers:	<i>Pseudo-prescriptions</i>	77%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		1,0%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		50,93%
Median age		75 y.
Max/min ratio ² of the median age (by district*)		1
Percentage of women		54,7%
Ratio Preferential rate/General rate		0,86
Coefficient of variation (2023)		15,8%
Max/min ratio ² of percentage of insured consumers (by district*)		1,65
CONSUMPTION		
Annual consumption (DDD)		1.292.501
Consumption of DDD (per 100.000 insured persons)		53.360
Average annual consumption per insured consumer (in DDD)		1
Percentage insured consumers with more than 3 times the average consumption		0,00%
Coefficient of variation ³ (2015-2017)		10,18%
Coefficient of variation ³ (2021-2023)		14,49%
Trend ⁴ (2015-2023)		0,10%
Trend ⁵ (2015-2021)		1,67%
Trend ⁵ (2021-2023)		-4,45%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		17.198.561€
Average annual expenditure per insured		7,1€
Average patient share per insured consumer		21,8%
Max/Min Ratio ² of expenditure per insured (by district*)		1,64
Percentage low-cost medication		NA
Trend (2015-2023)		7,18%
Trend (2021-2023)		-2,77%

Link to the report: [RAPPORT-EN-Vaccination contre la grippe hors MRS-MRPA 65 et plus 2023.pdf](#)

12. CROSS-SYSTEM ANALYSES

Polypharmacy (65 years and older)

Main prescribers:	General practitioners	79%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		31,8%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	43,71%	
Median age	76 y.	
Max/min ratio ² of the median age (by district*)	1,04	
Percentage of women	54,7%	
Ratio Preferential rate/General rate	1,31	
Coefficient of variation (2023)	7,7%	
Max/min ratio ² of percentage of insured consumers (by district*)	1,35	
CONSUMPTION		
Annual consumption (DDD)	2.167.516.806	
Consumption of DDD (per 100.000 insured persons)	89.484.758	
Average annual consumption per insured consumer (in DDD)	2.047	
Percentage insured consumers with more than 3 times the average consumption	0,41%	
Coefficient of variation ³ (2020-2022)	9,23%	NS
Coefficient of variation ³ (2021-2023)	9,04%	
Trend ⁴ (2020-2023)	1,14%	***
Trend ⁵ (2020-2021)	0,68%	NA
Trend ⁵ (2021-2023)	1,37%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	990.887.744€	
Average annual expenditure per insured	409,08€	
Average patient share per insured consumer	11,5%	
Max/Min Ratio ² of expenditure per insured (by district*)	1,37	
Percentage low-cost medication	69,4%	
Trend (2020-2023)	5,55%	
Trend (2021-2023)	6,92%	

Link to the report: [RAPPORT-EN-Polymedication_65_et_plus_min_80_DDD_2023.pdf](#)

Medication use – SUMMARY

Anticholinergics (65 years and older)

Main prescribers:	<i>General practitioners</i>	85%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) ¹		37,4%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		17,77%
Median age		75 y.
Max/min ratio ² of the median age (by district*)		1,04
Percentage of women		65,5%
Ratio Preferential rate/General rate		1,54
Coefficient of variation (2023)		11,8%
Max/min ratio ² of percentage of insured consumers (by district*)		1,52
CONSUMPTION		
Annual consumption (DDD)		135.281.540
Consumption of DDD (per 100.000 insured persons)		5.585.025
Average annual consumption per insured consumer (in DDD)		314
Percentage insured consumers with more than 3 times the average consumption		2,87%
Coefficient of variation ³ (2020-2022)		13,02%
Coefficient of variation ³ (2021-2023)		13,06%
Trend ⁴ (2020-2023)		-0,09%
Trend ⁵ (2020-2021)		0,31%
Trend ⁵ (2021-2023)		-0,28%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		42.872.285€
Average annual expenditure per insured		17,7€
Average patient share per insured consumer		20,9%
Max/Min Ratio ² of expenditure per insured (by district*)		1,49
Percentage low-cost medication		86,1%
Trend (2020-2023)		-0,84%
Trend (2021-2023)		-0,14%

Link to the report: [RAPPORT-EN-Anticholinergiques_65_et_plus_min_80_DDD_2023.pdf](#)

13. FOOTNOTES

- 1 Approximate value estimated from the discrepancy between the sales declarations of wholesalers to pharmacies converted into DDD and what is paid by the health insurance and the patients' share (see Annex D). This is a contextual indicator.
- 2 An 'NA' result indicates a ratio, which cannot be calculated, i.e. the minimum value equals zero.
- 3 The test compares the coefficients of variation for the two periods and indicates whether the difference is statistically significant.
- 4 The test indicates whether the observed slope is statistically significantly different from 0%.
- 5 The test indicates whether the break in trend between the two periods is statistically significant.